secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalon GloboCare Corp. (ALBT)
CIK:        0001630212
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001213900-25-014619
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology
--------------------------------------------------------------------------------

- Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.
- Patent covers bispecific anti-CD19xCD22 CAR design and localized cytokine induction to enhance CAR cell cytotoxicity, survival, and proliferation.
- Technology aims to improve expansion, manufacturing, and efficacy of CAR-T and CAR-NK cells for cancer treatment.
- Extends Avalon's global IP footprint to China, supplementing existing U.S. and PCT protections.
- CEO David Jin highlights potential for practical, cost-effective point-of-care cancer solutions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/0001213900-25-014619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/ea0231383-8k_avalon.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-014619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer